Kapitalradar

Swiss capital increases, read from the official gazette and scored for financing rounds.

updated every weekdayrelease r10data as of 8 Oct 2026

↺ Try a rewind: Soverli AG on 24 Sep 2025, 83 days before the round was announced

Release evaluation · 7 Oct 2026 · does not rewind · rules + Claude: precision 2%–100% (n=17), recall 16/30 announced rounds · rules-only: precision 1%–99% (n=29), recall 18/30 announced rounds · Methodology

← Back to the feed

OphthaNova Therapeutics AG

History from 19 Aug 2025

UID
CHE-485.039.892
Legal form
AG
Canton
ZH
Founded
19 Aug 2025
Amount raised
not in the SHAB
Lead investor
not in the SHAB
Nominal capital · CHFCHF 112k
28k56k84k112k4 Jun 2026 · CHF 112k
  • shares

Record

  1. Company formed

    Founded 19 Aug 2025

    SHAB HR01-1006414141 ↗
  2. Capital increase

    Likely financing

    Paid in cash

    Nominal capital
    100’000 → 111’525.40
    Shares
    100’000 → 1’115’254
    New shares, % of post-step shares
    — (nominal value per share changed)

    Aktienkapital neu: CHF 111'525.40 [bisher: CHF 100'000.00]. Liberierung Aktienkapital neu: CHF 111'525.40 [bisher: CHF 100'000.00]. Aktien neu: 1'115'254 Namenaktien zu CHF 0.10 [bisher: 100'000 Namenaktien zu CHF 1.00].

    From the SHAB entry · German original, person names removed · not an official copy · full entry ↗
    • The increase is an odd amount in small-nominal shares, as priced rounds usually are.+1.0
    • The company was founded less than six years before this capital increase.+0.5

    Classifier score 0.85 · likely-financing threshold 0.60 · not a calibrated probability

    SHAB HR02-1006666975 ↗

Published by 8 Oct 2026